国新健康(000503) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast The company expects to record a loss in the first half of 2025, with the loss expanding year-on-year, while operating revenue declines compared to the same period last year and basic earnings per share loss increases - The performance forecast covers the period from January 1, 2025, to June 30, 2025[2] Performance Forecast Summary | Item | Current Period (2025H1) | Prior Period (2024H1) | Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 100.13 million yuan | 137.39 million yuan | ↓ 27.1% | | Net Profit Attributable to Shareholders of Listed Company | Loss: approx. -89.21 million yuan | Loss: -72.98 million yuan | Loss expanded by 22.2% | | Net Profit After Deducting Non-Recurring Gains and Losses | Loss: approx. -88.91 million yuan | Loss: -78.37 million yuan | Loss expanded by 13.4% | | Basic Earnings Per Share | Loss: approx. -0.0911 yuan/share | Loss: -0.0745 yuan/share | Loss expanded | Pre-Audit Status of Performance Forecast The financial data disclosed in this performance forecast are preliminary results from the company's internal calculations and have not been audited by a certified public accountant - The financial data related to this performance forecast have not been audited by a certified public accountant[3] Explanation of Performance Changes The company's performance changes are primarily influenced by the seasonal nature of its business, exhibiting a 'lower in the first half, higher in the second half' pattern, with first-half revenue and profit remaining at annual lows despite ongoing focus on 'Three Medical Synergies' reform and health big data application and service innovation - The company's business exhibits significant seasonality, generally showing a 'lower in the first half, higher in the second half' trend, leading to performance pressure in the first half[4] - The company's strategic core revolves around the 'Healthy China' and 'Three Medical Synergies' reforms, focusing on the 'collection, integration, and utilization' of health big data, with an emphasis on medical insurance fund management, healthcare quality and safety, pharmaceutical and medical device regulation, and health service innovation[4] Risk Warning The company explicitly states that this performance forecast data is a preliminary estimate by the finance department, unaudited, and the final accurate financial data will be disclosed in the 2025 semi-annual report, advising investors to make cautious decisions - This performance forecast data is a preliminary estimate by the company's finance department, unaudited by a certified public accountant, and thus subject to uncertainty[5] - The company reminds investors to rely on the detailed financial data disclosed in the 2025 semi-annual report for decision-making, exercise caution, and be aware of investment risks[5][6]